AUC passes with 0.05 and Cmax with 0.0294 [Two-Stage / GS Designs]

posted by Mikalai  – Belarus, 2019-09-18 16:56  – Posting: # 20611
Views: 2,223

Dear Helmut,

» 1. If interim power is <80%, your assumptions about the CV were not correct. Assess the study with the adjusted α 0.0294.
»    a. If you pass, stop.

What prevents us from evaluating the bioequivalence at α-level of 5% as the first step, and if we pass the bioequivalence criteria, we stop the trial. If we fail, we then evaluate the power. If power is more than 80% for the failed parameter, we stop the trial and we are done. If power is less than 80% for the failed parameter, then we go the next stage and adust α-level correspondingly to preserve overall α-level at 0,5. Of course, this should be written in the protocol and is a deviation, maybe a big one, from Potvin C method.
Regards,
Mikalai

Complete thread:

Activity
 Admin contact
20,345 posts in 4,273 threads, 1,402 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 20:16 CET

No one wants to learn from mistakes, but we cannot learn enough
from successes to go beyond the state of the art.    Henry Petroski

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5